Shanghai Exchange to Launch Two New Tech-Focused Stock Indexes

China’s main stock exchange is adding two new measuring sticks for investors who want to bet on the country’s technology ambitions. The Shanghai Stock Exchange, together with index compiler China Securities Index Co., will officially launch the SSE Innovative Drug STAR Leading Index and the SSE STAR Market Software Services Index on September 29, 2026, according to an announcement carried by financial news outlet Gelonghui. The two gauges are designed to give the market more diverse investment targets and clearer windows into two of China’s most closely watched industries.

The innovative drug index will draw 40 companies from the STAR Market and the main Shanghai board that score highly on research spending and growth potential in drug development. The STAR Market, known in Chinese as the Kechuangban, is Shanghai’s Nasdaq-style board for science and technology firms, and the new index deliberately gives extra weight to STAR-listed names. That tilt reflects how much of China’s biotech activity now clusters on the board, where loss-making but research-heavy drug developers can list. For global investors, the index offers a single number to watch as Chinese pharma shifts from making generic copies to inventing novel treatments.

The second index tracks software services companies on the STAR Market. China’s software sector spans everything from enterprise cloud tools to industrial design programs, and it has become a priority as the country pushes to reduce reliance on foreign suppliers of key business software. By packaging these companies into an investable index, the exchange is effectively creating a benchmark that fund managers can use to build products such as exchange-traded funds.

Index launches of this kind are common in China and often precede the listing of tracking funds, though the exchange did not say whether any asset manager has already filed to create one. The announcement fits a broader pattern in which Chinese exchanges roll out themed indexes to channel household savings toward strategic industries. Recent years have seen a steady stream of indexes covering semiconductors, artificial intelligence, electric vehicles and clean energy.

Investor appetite for such themes has been uneven. Biotech stocks in China have swung sharply as drug approvals, overseas licensing deals and pricing rules reshape the sector. Software names, meanwhile, have benefited from a national push for domestic alternatives to foreign systems, but many still struggle to turn rapid revenue growth into consistent profit. A dedicated index will not change those fundamentals, but it will make the sector’s collective performance easier to track and compare.

The timing is notable. Global markets have been volatile, with bond yields rising in the United States and Japan, and Chinese policymakers have been trying to steady domestic confidence. New investment products tied to innovation themes are one way to keep domestic capital engaged with the country’s long-term technology goals, even when short-term sentiment is shaky.

For international readers, the practical takeaway is simple: China is continuing to build financial infrastructure around its tech economy. Whether or not these particular indexes attract large sums, they signal where the exchange expects future growth to come from. Drug discovery and software services are both areas where Chinese firms increasingly compete globally, and the new benchmarks will give outsiders a cleaner way to follow that competition. The indexes take effect on September 29, and their early performance will be watched as a barometer of appetite for China’s innovation story.